New Mexico is currently home to 418 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Albuquerque, Santa Fe, Las Cruces and Farmington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Project: Every Child for Younger Patients With Cancer
NCT02402244
Recruiting
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.
Gender:
All
Ages:
25 years and below
Trial Updated:
02/27/2024
Locations: University of New Mexico Cancer Center, Albuquerque, New Mexico
Conditions: Central Nervous System Neoplasm, Childhood Immature Teratoma, Childhood Langerhans Cell Histiocytosis, Childhood Mature Teratoma, Congenital Mesoblastic Nephroma, Lymphoproliferative Disorder, Myeloproliferative Neoplasm, Stromal Neoplasm, Carcinoma In Situ, Malignant Solid Neoplasm, Desmoid Fibromatosis, Ganglioneuroma, Melanocytic Neoplasm, Neuroendocrine Neoplasm
Register for Updates
A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN
NCT05856760
Recruiting
This is a 28-week, open-label, multicenter, single-group Phase 2 exploratory study to determine the safety and effect of sparsentan in participants with IgAN who are at risk of disease progression to kidney failure despite being on both stable RAASi and SGLT2 inhibitor treatment for at least 12 weeks prior to study entry
Gender:
All
Ages:
18 years and above
Trial Updated:
02/22/2024
Locations: Travere Investigational Site, Albuquerque, New Mexico
Conditions: Immunoglobulin A Nephropathy
Register for Updates
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
NCT04831580
Recruiting
This is a randomized controlled trial to compare survival for patients who undergi robotic assisted laparoscopy versus open radical hysterectomy and lymph node assessment for the treatment of early stage cervical cancer.
Gender:
Female
Ages:
18 years and above
Trial Updated:
02/21/2024
Locations: University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico
Conditions: Cervical Cancer
Register for Updates
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
NCT05565378
Recruiting
This study will evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PDy) of novel immunotherapy combinations compared with immunotherapy monotherapy in participants with Programmed death ligand-1 (PD L-1) high (Tumor cells [TC]/ Tumor proportion score [TPS] ≥ 50%), previously untreated, unresectable, locally advanced or metastatic NSCLC. Drug name mentioned as Belrestotug, GSK4428859A, and EOS884448 are all interchangeable for the same compound. In the rest of the documen... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/20/2024
Locations: GSK Investigational Site, Albuquerque, New Mexico
Conditions: Lung Cancer, Non-Small Cell
Register for Updates
Standing Strong in Tribal Communities: Assessing Elder Falls Disparity
NCT04876729
Recruiting
Falls and fall-related injuries are major health risks in American Indian elders. The data showed 52 percent of Zuni elders reporting a fall during the past year, which is significantly higher than the US national average of one out of three adults older then 65 years. In partnership with Zuni Pueblo leadership and community stake holders, the feasibility will be reviewed in hopes of implementing Community Health Representative delivered fall risk screening and evidence-based Otago Exercise Prog... Read More
Gender:
All
Ages:
65 years and above
Trial Updated:
02/19/2024
Locations: Zuni Health Initiative, Zuni Pueblo, New Mexico
Conditions: Fall
Register for Updates
A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer
NCT05723562
Recruiting
The purpose of this study is to investigate dostarlimab monotherapy in participants with locally advanced Mismatch-repair deficient (dMMR)/Microsatellite instability-high (MSI-H) rectal cancer who have received no prior treatment. Participants who achieve complete clinical response (cCR) following dostarlimab treatment will undergo non-operative management (NOM), including close surveillance for recurrent disease. The goal of the study is to determine if Dostarlimab therapy alone is an effective... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/18/2024
Locations: GSK Investigational Site, Albuquerque, New Mexico
Conditions: Neoplasms, Rectal
Register for Updates
Improving Medical Decision Making for Older Patients With End Stage Renal Disease
NCT04347629
Recruiting
The overall objective of this study is to reduce the burden of chronic kidney disease (CKD) and its consequences for an aging U.S. population. To accomplish this, the investigators propose to conduct a multi-center randomized trial of an advance care planning (ACP) video intervention (vs. usual care) among older patients with CKD.
Gender:
All
Ages:
65 years and above
Trial Updated:
02/16/2024
Locations: The University of New Mexico Health Sciences Center, Albuquerque, New Mexico
Conditions: Renal Disease, End Stage, Palliative Care, Decision Aids
Register for Updates
Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD
NCT06011577
Recruiting
A Phase 3, randomized, double-blind, placebo-controlled, multicenter trial of REL-1017 in patients with major depressive disorder (MDD).
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
02/15/2024
Locations: Relmada Site, Albuquerque, New Mexico
Conditions: Major Depressive Disorder, Depression
Register for Updates
A Study Evaluating Potential Disease-Mediated Drug-Drug Interaction in Adult Participants With Active Eosinophilic Esophagitis Receiving Cendakimab
NCT05175352
Recruiting
The purpose of this study to evaluate the potential for disease-mediated drug-drug interactions between cendakimab and selected substrates of metabolic enzymes in eosinophilic esophagitis participants.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
02/15/2024
Locations: New Mexico Clinical Research and Osteoporosis Center, Albuquerque, New Mexico
Conditions: Eosinophilic Esophagitis
Register for Updates
Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction
NCT02901184
Recruiting
Heart failure with preserved ejection fraction (HFPEF) is common and deadly but without therapy. Inconclusive studies such as TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) suggest spironolactone may be effective in HFPEF, but it is generic and will not be studied by industry. SPIRRIT is a unique Registry-Randomized Clinical Trial (RRCT) that will test the hypothesis that spironolactone plus standard of care compared to standard of care alone reduc... Read More
Gender:
All
Ages:
Between 50 years and 99 years
Trial Updated:
02/15/2024
Locations: University of New Mexico Health Science Center, Albuquerque, New Mexico
Conditions: Heart Failure With Preserved Ejection Fraction
Register for Updates
Real-world Experience of Catheter Ablation for the Treatment of Paroxysmal and Persistent Atrial Fibrillation
NCT04088071
Recruiting
The primary purpose of this registry is to obtain real-world clinical experience of Paroxysmal (PAF) and Persistent (PsAF) Atrial Fibrillation ablation radiofrequency (RF) technologies. Data from the registry will be used to assess clinical outcomes, including procedural efficiency, safety, and long-term, effectiveness of catheter ablation with novel RF technologies in PAF and PsAF patients.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/14/2024
Locations: Lovelace Health System, Albuquerque, New Mexico
Conditions: Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
Register for Updates
Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout
NCT05818085
Recruiting
This is a multicenter, randomized, double-blind, Phase 2b/3 study to evaluate the efficacy and safety of ABP-671. Part 1 of the study will compare the efficacy and safety of different doses and regimens of ABP-671 with placebo and allopurinol. Part 2 of the study will compare the dosing regimen(s) of ABP-671 selected from Part 1 with placebo in participants who have not been enrolled for Part 1.
Gender:
All
Ages:
Between 19 years and 69 years
Trial Updated:
02/08/2024
Locations: Inspire Santa Fe Medical Group, Santa Fe, New Mexico
Conditions: Gout
Register for Updates